UCB Partners in Economics and Health Outcomes


ATLANTA, GA. – UCB today announced three collaborations aimed at examining the impact of crisis clusters on the quality of life of patients and caregivers. Collaborations with Le Bonheur Children’s Hospital, Wisconsin Health Information Organization (WHIO), and Yale University will uncover and harness the power of education and global evidence (RWE) to fill this research gap, expand awareness, and embrace positive changes in health outcomes for people with seizure clusters.

Seizure clusters are episodes of increased seizure activity, in which two or more seizures occur in a 24 hour period. It is estimated that more than 150,000 people in the United States with uncontrolled epilepsy also experience seizure clusters. Due to their unpredictable nature, these disruptive events can make people with epilepsy feel anxious, worried, frustrated or isolated, further fueling the decline in mental health of this patient population.

“Our real-world evidence and educational collaborations with Le Bonheur Children’s Hospital, the Wisconsin Health Information Organization, and Yale University illustrate our desire to make a meaningful contribution to how physicians, patients, and the entire community health care system think about and treat clusters of seizures. This includes how we frame and account for the value of treatments within the health care ecosystem,” said Brad Chapman, Chief of Epilepsy and Rare Syndromes at the States United at UCB.” We know that rescue medication that allows adults and adolescents to quickly return to daily activities is particularly important, whether in the classroom or in everyday life, and we are committed to providing solutions that reinforce this ambition.”

Project with Le Bonheur Children’s Hospital aims to improve the lived experience of patients with epilepsy by developing resources designed specifically for patients and caregivers that address the importance of proper use of rescue medication outside the hospital. This “Ask the Experts” project aims to address identified gaps in patient and caregiver education and information regarding epilepsy and specifically seizure clusters through the development of an educational resource and ‘a video.

“We know that most seizure clusters occur at home or during other daily activities; treating clusters of seizures where and when they occur is critical for best patient outcomes,” said Dr. James Wheless, BScPharm, MD, FAAP, FAAN, FAES, Co-Director. from the Institute of Neurosciences, Le Bonheur Children’s Hospital. “As school begins and COVID-19 remains a medical concern, it is of the utmost importance that we prepare students to start their school year off right with a seizure action plan and appropriate rescue medications so they can prepare their teachers and school nurses to act when the cluster starts.”

The collaboration with WHIO aims to understand the economic and clinical impact of undertreating seizure clusters and to explore the drivers of better outcomes. This project will analyze retrospective claims at the state level to examine trends in prescribing, health care utilization, costs, barriers to access, and disease prevalence.

Dr. George Morris, MD, MPH, FAAN, FAES, Milwaukee-area epileptologist and valued partner of the WHIO project, explains, “The impact of epilepsy on a person’s health and quality of life is significantly affected by clusters of seizures. the health risk associated with aspiration and the terrifying experience of the patient, family and friends is unique to epilepsy. This project uses a single data source to see the full effects on almost all patients in Wisconsin. We’re excited to learn what factors can help reduce seizure clusters to educate providers and patients on best practices.”

The Yale University project, Reducing Seizures Through Education and Support (ROSES), aims to increase understanding of crisis cluster management, bring new insights to clinical management and patient-centered care. patient, and improve the overall quality of epilepsy care. Specifically, this study is designed to assess the impact of seizure rescue medications, treatment regimens, healthcare resource utilization, clinic quality improvement tools (i.e., i.e. crisis action plans) and the patient/caregiver experience.

About Epilepsy1-4
Epilepsy is a chronic neurological disorder of the brain. It is the fourth most common neurological condition in the world and affects around 65 million people. In the United States, more than 3.4 million people suffer from epilepsy. Anyone can develop epilepsy; it occurs in all ages, races, and genders, and is defined as one or more unprovoked seizures with a risk of further seizures.

About Seizure Clustersi-10
Of the one-third of patients living with uncontrolled epilepsy, it is estimated that more than 150,000 people in the United States with intractable epilepsy also experience seizure clusters. Seizure clusters are generally defined as acute episodes of consecutive seizures that occur within a short period of time with a patient regaining consciousness during the interictal period. These clusters also differ from a person’s typical seizure pattern. Other names for seizure clusters include acute repetitive seizures (ARS), serial seizures, crescendo seizures, and burst seizures, which highlight the repetitive nature of seizures. Seizure clusters are a form of epileptic urgency that can progress to prolonged seizures or status epilepticus.

About UCB in Epilepsy
UCB has a rich heritage in the field of epilepsy with over 20 years of experience in the research and development of antiepileptic drugs. As a company with a long-term commitment to epilepsy research, our goal is to meet unmet medical needs. Our scientists are proud to contribute to advances in the understanding of epilepsy and its treatment. We partner and create supernetworks with world-renowned scientists and clinicians at academic institutions, pharmaceutical companies and other organizations who share our goals. At UCB, we are inspired by patients and guided by science in our commitment to supporting patients with epilepsy.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.


About Author

Comments are closed.